These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

417 related articles for article (PubMed ID: 14702090)

  • 1. Short-term lithium treatment promotes neuronal survival and proliferation in rat striatum infused with quinolinic acid, an excitotoxic model of Huntington's disease.
    Senatorov VV; Ren M; Kanai H; Wei H; Chuang DM
    Mol Psychiatry; 2004 Apr; 9(4):371-85. PubMed ID: 14702090
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neurogenesis in the striatum of the quinolinic acid lesion model of Huntington's disease.
    Tattersfield AS; Croon RJ; Liu YW; Kells AP; Faull RL; Connor B
    Neuroscience; 2004; 127(2):319-32. PubMed ID: 15262322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The IGF-I amino-terminal tripeptide glycine-proline-glutamate (GPE) is neuroprotective to striatum in the quinolinic acid lesion animal model of Huntington's disease.
    Alexi T; Hughes PE; van Roon-Mom WM; Faull RL; Williams CE; Clark RG; Gluckman PD
    Exp Neurol; 1999 Sep; 159(1):84-97. PubMed ID: 10486177
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transplanted adult neural progenitor cells survive, differentiate and reduce motor function impairment in a rodent model of Huntington's disease.
    Vazey EM; Chen K; Hughes SM; Connor B
    Exp Neurol; 2006 Jun; 199(2):384-96. PubMed ID: 16626705
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Susceptibility of striatal neurons to excitotoxic injury correlates with basal levels of Bcl-2 and the induction of P53 and c-Myc immunoreactivity.
    Liang ZQ; Wang XX; Wang Y; Chuang DM; DiFiglia M; Chase TN; Qin ZH
    Neurobiol Dis; 2005 Nov; 20(2):562-73. PubMed ID: 15922606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Temporal profile of subventricular zone progenitor cell migration following quinolinic acid-induced striatal cell loss.
    Gordon RJ; Tattersfield AS; Vazey EM; Kells AP; McGregor AL; Hughes SM; Connor B
    Neuroscience; 2007 Jun; 146(4):1704-18. PubMed ID: 17459592
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blockade of quinolinic acid-induced neurotoxicity by pyruvate is associated with inhibition of glial activation in a model of Huntington's disease.
    Ryu JK; Kim SU; McLarnon JG
    Exp Neurol; 2004 May; 187(1):150-9. PubMed ID: 15081596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nuclear factor-kappaB-dependent cyclin D1 induction and DNA replication associated with N-methyl-D-aspartate receptor-mediated apoptosis in rat striatum.
    Liang ZQ; Wang X; Li LY; Wang Y; Chen RW; Chuang DM; Chase TN; Qin ZH
    J Neurosci Res; 2007 May; 85(6):1295-309. PubMed ID: 17385714
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adenosine A2A receptor blockade before striatal excitotoxic lesions prevents long term behavioural disturbances in the quinolinic rat model of Huntington's disease.
    Scattoni ML; Valanzano A; Pezzola A; March ZD; Fusco FR; Popoli P; Calamandrei G
    Behav Brain Res; 2007 Jan; 176(2):216-21. PubMed ID: 17123640
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intracerebral implantation of NGF-releasing biodegradable microspheres protects striatum against excitotoxic damage.
    Menei P; Pean JM; Nerrière-Daguin V; Jollivet C; Brachet P; Benoit JP
    Exp Neurol; 2000 Jan; 161(1):259-72. PubMed ID: 10683292
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beneficial effects of rolipram in a quinolinic acid model of striatal excitotoxicity.
    DeMarch Z; Giampà C; Patassini S; Martorana A; Bernardi G; Fusco FR
    Neurobiol Dis; 2007 Feb; 25(2):266-73. PubMed ID: 17184995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phosphodiesterase 10 inhibition reduces striatal excitotoxicity in the quinolinic acid model of Huntington's disease.
    Giampà C; Patassini S; Borreca A; Laurenti D; Marullo F; Bernardi G; Menniti FS; Fusco FR
    Neurobiol Dis; 2009 Jun; 34(3):450-6. PubMed ID: 19281846
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Behavioral and anatomical effects of quinolinic acid in the striatum of the hemiparkinsonian rat.
    Olds ME; Jacques DB; Kopyov O
    Synapse; 2005 Jan; 55(1):26-36. PubMed ID: 15499610
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relative survival of striatal projection neurons and interneurons after intrastriatal injection of quinolinic acid in rats.
    Figueredo-Cardenas G; Anderson KD; Chen Q; Veenman CL; Reiner A
    Exp Neurol; 1994 Sep; 129(1):37-56. PubMed ID: 7925841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulation of striatal quinolinate neurotoxicity by elevation of endogenous brain kynurenic acid.
    Harris CA; Miranda AF; Tanguay JJ; Boegman RJ; Beninger RJ; Jhamandas K
    Br J Pharmacol; 1998 May; 124(2):391-9. PubMed ID: 9641558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Neuroprotective actions of lithium].
    Hashimoto R; Fujimaki K; Jeong MR; Senatorov VV; Christ L; Leeds P; Chuang DM; Takeda M
    Seishin Shinkeigaku Zasshi; 2003; 105(1):81-6. PubMed ID: 12701214
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lithium suppresses excitotoxicity-induced striatal lesions in a rat model of Huntington's disease.
    Wei H; Qin ZH; Senatorov VV; Wei W; Wang Y; Qian Y; Chuang DM
    Neuroscience; 2001; 106(3):603-12. PubMed ID: 11591460
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Striatal modulation of cAMP-response-element-binding protein (CREB) after excitotoxic lesions: implications with neuronal vulnerability in Huntington's disease.
    Giampà C; DeMarch Z; D'Angelo V; Morello M; Martorana A; Sancesario G; Bernardi G; Fusco FR
    Eur J Neurosci; 2006 Jan; 23(1):11-20. PubMed ID: 16420411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AAV-mediated delivery of BDNF augments neurogenesis in the normal and quinolinic acid-lesioned adult rat brain.
    Henry RA; Hughes SM; Connor B
    Eur J Neurosci; 2007 Jun; 25(12):3513-25. PubMed ID: 17610571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined minocycline plus pyruvate treatment enhances effects of each agent to inhibit inflammation, oxidative damage, and neuronal loss in an excitotoxic animal model of Huntington's disease.
    Ryu JK; Choi HB; McLarnon JG
    Neuroscience; 2006 Sep; 141(4):1835-48. PubMed ID: 16809003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.